Get the Stockscreener App
2.26
0.44%
-0.01
Century Therapeutics Inc stock is traded at $2.26, with a volume of 531.88K.
It is down -0.44% in the last 24 hours and down -7.57% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.27
Open:
$2.3
24h Volume:
531.88K
Relative Volume:
0.46
Market Cap:
$407.60M
Revenue:
$109.16M
Net Income/Loss:
$-107.78M
P/E Ratio:
-2.0428
EPS:
-1.1063
Net Cash Flow:
$-95.45M
1W Performance:
-3.42%
1M Performance:
-7.57%
6M Performance:
+361.22%
1Y Performance:
+293.59%
1-Day Range:
$2.25
$2.34
1-Week Range:
$2.10
$2.344
52-Week Range:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.26 | 409.41M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Point72 group reports 5.96M-share stake in Century Therapeutics (IPSC) - Stock Titan
RTW Investments and R. Wong report 7.1% stake in Century Therapeutics (IPSC) - Stock Titan
Century Therapeutics 1Q Research and Development Expenses $17.1M >IPSC - Moomoo
Versant Venture Management, LLC's Century Therapeutics Inc(IPSC) Holding History - GuruFocus
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Investing News Network
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics (IPSC) Gains +1.80% — Support Holds at $2.20 2026-05-14Long Setup - newser.com
Century Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Century Therapeutics Reports First Quarter Financial Results and Business Updates - Investing News Network
Century Therapeutics Reports Q1 2026 Financial Results, Advances iPSC-Derived Diabetes and Cancer Therapies, Cash Runway to 2029 - Minichart
Century Therapeutics Q1 Earnings Beat Expectations - Intellectia AI
Century Therapeutics reports Q1 net loss $21.6M, cash runway into Q1 2029 - TradingView
Century Therapeutics 1Q 2026: Revenue ($22.26M), Net income ($21.65M), EPS ($0.11) — 10-Q Summary - TradingView
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend - TradingView
Century Therapeutics (NASDAQ: IPSC) swings to Q1 2026 loss as prior collaboration revenue rolls off - Stock Titan
Century Therapeutics (IPSC) swings to Q1 2026 loss as one-time collaboration revenue ends - Stock Titan
TradingKey - TradingKey
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock By Investing.com - Investing.com South Africa
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock - Investing.com India
SVP at Century Therapeutics (IPSC) sells shares to cover taxes - Stock Titan
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedROE - newser.com
Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
H.C. Wainwright Increases Century Therapeutics Price Target to Five Dollars - HarianBasis.co
Century Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC) - Insider Monkey
Century Therapeutics Selected for Oral Presentation of CNTY?813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Century Therapeutics to present diabetes therapy data at ADA - Investing.com
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Century Therapeutics to present diabetes therapy data at ADA By Investing.com - Investing.com Canada
Century Therapeutics (NASDAQ: IPSC) sets 2026 virtual meeting and share authorization vote - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart.com
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading.Margin of Safety - UBND thành phố Hải Phòng
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
IPSC Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
H.C. Wainwright raises Century Therapeutics price target on diabetes therapy potential - Investing.com Canada
Century Therapeutics (IPSC) Stock: Market Signals (Investor Concern) 2026-04-20Viral Momentum Trades - Newser
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Mar 12 '26 |
Sale |
2.55 |
7,043 |
17,953 |
507,261 |
| Russotti Gregory | See Remarks |
Mar 12 '26 |
Sale |
2.55 |
10,076 |
25,684 |
515,427 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):